Series - Raising Capital

A private biotech that announces a definitive agreement with a SPAC jumps into the public investor spotlight and faces that attention with fewer guardrails than the IPO process, plus a need to transform board, investor, and regulatory relations. Given that most SPAC merger deals also involve follow-on PIPE investment rounds or other transactions, the full fundraising benefits of the deal strategy require a smooth de-SPAC process that a private biotech would never have encountered before. View this webinar to learn best practices for navigating from SPAC deal announcement through de-SPAC process to regular life managing a publicly traded company.  

Innovation flourishes when science and consumer values are aligned and complement one another. Regulatory approaches towards innovative products cannot exist in isolation. They should be supported by credible transparency measures. A proactive approach to transparency stands to build trust and foster an inclusive environment to address our most pressing societal, nutritional, and environmental concerns. This webinar will explore the meaningful – and sometimes unexpected- actions and partnerships that are growing trust in the innovation ecosystem and delivering access to innovations that benefit people and the planet. 
 

New algorithms and optical system improvements are expanding the frontier of cell imaging quality. Artificial intelligence techniques enable better visualization of cellular mechanisms in a wide number of applications and across multiple scientific disciplines, including advancing neurological research. View this Biotechnology Innovation Organization (BIO) webinar as it highlights how AI and imaging are being used to improve our understanding of complex and notoriously intractable disorders such as Alzheimer’s, Dementia, and related diseases. Learn from the following imaging and therapeutic development experts as they answer audience questions during the session.  

Accepting the Status Quo: Subject Matter Eligibility Nearly a Decade after Mayo  

This Biotechnology Innovation Organization (BIO) webinar discusses the reality that almost a decade after the Supreme Court’s decision in Mayo v. Prometheus, the current subject matter eligibility standard has become the status quo with little prospect for change. Speakers will discuss how innovators can best protect their technology under these circumstances, how subject matter jurisprudence has impacted the patent process, and whether incremental changes could improve the situation.  

The Biotechnology Innovation Organization (BIO) and BioFlorida present "The Transformative Potential of Genomic Medicine 2.0." Genomic technologies create powerful tools that have the potential to diagnose, treat, and permanently subdue many human diseases. Technologies such as gene therapy, gene editing, and CRISPR are just some of the newest terms as researchers and clinicians work on new approaches to develop lifesaving, disease-altering treatments. This session provides in-depth discussion regarding how treatment is changing in rare diseases and the sickle cell community, and how public and private payers are approaching coverage of these crucial treatments. The session opens with statements from two legislators, then the panel features two patients and an expert in alternative payment models to provide information and answer questions from policymakers.  

Representative Sam Garrison
Florida House of Representatives
House Health and Human Services Committee Republican Majority Whip

Senator Bobby Powell
Florida State Senate
Legislative Black Caucus Chair

Nearly 30 life science SPAC deals have closed or announced definitive agreements within the past year, helping private companies access new capital and public markets quickly. However, even recent traditions in SPAC deal terms continue to evolve because of statements from regulators regarding the accounting for warrants, shifts in investor expectations, and the availability of PIPE deal supporters, among other factors. View this Biotechnology Innovation Organization (BIO) webinar's discussion of best practices for negotiating SPAC deal terms in today’s market to maximize raising capital to serve biomedical innovation. Learn from the following deal-making experts as they answer audience questions during the session.  

This session is part of the "Anatomy of a SPAC Deal" Webinar Series, sponsored by Chardan.

More than 60 public Special Purpose Acquisition Companies (SPACs) are currently seeking life science companies for merger deals. Join this Biotechnology Innovation Organization (BIO) webinar to learn which financial, scientific, and managerial characteristics are most appealing to SPAC sponsors and the critical factors biotech management teams should prioritize in reviewing SPACs as potential fundraising sources. Learn from the following deal-making experts as they answer the moderator's and the audience's questions during the session.  

This session is part of BIO's "Anatomy of a SPAC Deal" Webinar Series, sponsored by Chardan.

Calculating the Benefits of Biotechnology Climate change is a clear and present danger to society. Industries and governments are taking action to confront this crisis, committing to sustainability goals that reduce environmental impact and improve the health and well-being of communities. To be confident in sustainability claims, it is critical to accurately calculate the environmental benefits of biotechnologies and how that value transfers through complex supply chains. Our BIO Impact webinar will explore efforts to promote consistent sustainability accounting, as well as highlight BIO members’ transformative innovations and the partnerships & collaborations that are leveraging the demands of climate mitigation and propelling a resilient biobased economy of the future.

Join the Biotechnology Innovation Organization (BIO) for an expert discussion on Section 112, focusing on the enablement of functional language. We'll review how this is playing out in district court litigation and in the PTAB and also discuss potential prosecution strategies. The discussion will focus on recent enablement-related cases, including Amgen v. Sanofi and the cases that led to that landmark decision.